Home
KYMR
KYMR News

Latest Kymera Therapeutics Inc. (KYMR) News on December 18, 2024

MT Newswires

12 days ago

BMO Capital Initiates Kymera Therapeutics at Market Perform With $55 Price Target

MT Newswires

16 days ago

Kymera Therapeutics Shares Rise After Upgrade From Wells Fargo

MT Newswires

16 days ago

Wells Fargo Upgrades Kymera Therapeutics to Overweight, Price Target is $57

Kymera Therapeutics to Participate in Upcoming December Investor Conferences

GlobeNewswire

22 days ago

Kymera Therapeutics to Participate in Upcoming December Investor Conferences

Kymera Therapeutics to Participate in Upcoming November Investor Conferences

GlobeNewswire

a month ago

Kymera Therapeutics to Participate in Upcoming November Investor Conferences

MT Newswires

a month ago

UBS Adjusts Price Target on Kymera Therapeutics to $74 From $80, Maintains Buy Rating

Analysts Have Made A Financial Statement On Kymera Therapeutics, Inc.'s (NASDAQ:KYMR) Third-Quarter Report

Simply Wall St.

a month ago

Analysts Have Made A Financial Statement On Kymera Therapeutics, Inc.'s (NASDAQ:KYMR) Third-Quarter Report

Kymera Therapeutics Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag

Simply Wall St.

2 months ago

Kymera Therapeutics Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag

Kymera Q3 Loss Narrower Than Expected, Pipeline in Focus

Zacks

2 months ago

Kymera Q3 Loss Narrower Than Expected, Pipeline in Focus

MT Newswires

2 months ago

B. Riley Adjusts Price Target on Kymera Therapeutics to $41 From $36, Maintains Neutral Rating

Kymera Therapeutics Inc (KYMR) Q3 2024 Earnings Call Highlights: Strategic Advancements and ...

GuruFocus.com

2 months ago

Kymera Therapeutics Inc (KYMR) Q3 2024 Earnings Call Highlights: Strategic Advancements and ...

U.S. Drugmakers Are Breaking Up With Their Chinese Supply-Chain Partners

The Wall Street Journal

2 months ago

U.S. Drugmakers Are Breaking Up With Their Chinese Supply-Chain Partners

MT Newswires

2 months ago

Truist Trims Price Target on Kymera Therapeutics to $53 From $54, Keeps Buy Rating

MT Newswires

2 months ago

Kymera Therapeutics Shares Fall After Q3 Loss, Lower Revenue

Kymera Therapeutics, Inc. (KYMR) Reports Q3 Loss, Lags Revenue Estimates

Zacks

2 months ago

Kymera Therapeutics, Inc. (KYMR) Reports Q3 Loss, Lags Revenue Estimates

Kymera Therapeutics Announces Third Quarter 2024 Financial Results and Provides a Business Update

GlobeNewswire

2 months ago

Kymera Therapeutics Announces Third Quarter 2024 Financial Results and Provides a Business Update

Kymera Therapeutics Inc (KYMR) Q3 2024: Everything You Need To Know Ahead Of Earnings

GuruFocus.com

2 months ago

Kymera Therapeutics Inc (KYMR) Q3 2024: Everything You Need To Know Ahead Of Earnings

Voyager Therapeutics (VYGR) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Zacks

2 months ago

Voyager Therapeutics (VYGR) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Kymera Therapeutics, Inc. (KYMR) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

Zacks

2 months ago

Kymera Therapeutics, Inc. (KYMR) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

Kymera Therapeutics Announces Dosing of First Participant in Phase 1 Clinical Trial of KT-621, a First-in-Class Oral STAT6 Degrader, for the Treatment of TH2 Immuno-Inflammatory Diseases

GlobeNewswire

2 months ago

Kymera Therapeutics Announces Dosing of First Participant in Phase 1 Clinical Trial of KT-621, a First-in-Class Oral STAT6 Degrader, for the Treatment of TH2 Immuno-Inflammatory Diseases

Kymera Therapeutics to Report Third Quarter 2024 Financial Results on October 31

GlobeNewswire

2 months ago

Kymera Therapeutics to Report Third Quarter 2024 Financial Results on October 31

Kymera Therapeutics Announces Three Scientific Presentations at the EORTC-NCI-AACR 2024 Symposium

GlobeNewswire

2 months ago

Kymera Therapeutics Announces Three Scientific Presentations at the EORTC-NCI-AACR 2024 Symposium

Kymera's IND Application for STAT6 Degrader Gets FDA Clearance

Zacks

2 months ago

Kymera's IND Application for STAT6 Degrader Gets FDA Clearance

MT Newswires

2 months ago

Kymera Therapeutics Says US FDA Clears Investigational New Drug Application for KT-621

Kymera Therapeutics Announces FDA Clearance of Investigational New Drug Application for KT-621, a First-in-Class, Oral STAT6 Degrader

GlobeNewswire

2 months ago

Kymera Therapeutics Announces FDA Clearance of Investigational New Drug Application for KT-621, a First-in-Class, Oral STAT6 Degrader

MT Newswires

3 months ago

Oppenheimer Adjusts Kymera Therapeutics Price Target to $56 From $52, Maintains Outperform Rating

MT Newswires

3 months ago

Kymera Therapeutics Says its Potential IND KT-621 Reduced Inflammation in Preclinical Models

Kymera Therapeutics Presents Preclinical Data for KT-621, a Potent, Selective, First-In-Class, Oral STAT6 Degrader at the EADV Congress

GlobeNewswire

3 months ago

Kymera Therapeutics Presents Preclinical Data for KT-621, a Potent, Selective, First-In-Class, Oral STAT6 Degrader at the EADV Congress

Why Is Kymera Therapeutics (KYMR) Up 10.9% Since Last Earnings Report?

Zacks

3 months ago

Why Is Kymera Therapeutics (KYMR) Up 10.9% Since Last Earnings Report?

Kymera Therapeutics to Participate in Upcoming September Investor Conferences

GlobeNewswire

4 months ago

Kymera Therapeutics to Participate in Upcoming September Investor Conferences

MT Newswires

4 months ago

Kymera Therapeutics Shares Rise After Wolfe Research Upgrade

MT Newswires

4 months ago

Wolfe Research Upgrades Kymera Therapeutics to Outperform From Peer Perform

MT Newswires

4 months ago

Kymera Therapeutics Closes Upsized $225 Million Public Offering

Kymera Therapeutics Announces Closing of Upsized $225 Million Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

GlobeNewswire

4 months ago

Kymera Therapeutics Announces Closing of Upsized $225 Million Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Kymera (KYMR) to Raise $225 Million Through Offering of Shares

Zacks

4 months ago

Kymera (KYMR) to Raise $225 Million Through Offering of Shares

Avidity, Kymera raise fresh funds; Walgreens partners with BARDA

BioPharma Dive

4 months ago

Avidity, Kymera raise fresh funds; Walgreens partners with BARDA

MT Newswires

4 months ago

Kymera Therapeutics Prices $225 Million Offering of Common Shares, Warrants

Kymera Therapeutics Announces Pricing of $225 Million Public Offering

GlobeNewswire

4 months ago

Kymera Therapeutics Announces Pricing of $225 Million Public Offering

MT Newswires

4 months ago

Kymera Therapeutics Unveils $200 Million Public Offering -- Shares Slip After Hours

Kymera Therapeutics Announces Proposed Public Offering

GlobeNewswire

4 months ago

Kymera Therapeutics Announces Proposed Public Offering

Earnings Beat: Kymera Therapeutics, Inc. (NASDAQ:KYMR) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

Simply Wall St.

4 months ago

Earnings Beat: Kymera Therapeutics, Inc. (NASDAQ:KYMR) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

Kymera (KYMR) Q2 Loss Narrower Than Expected, Pipeline in Focus

Zacks

4 months ago

Kymera (KYMR) Q2 Loss Narrower Than Expected, Pipeline in Focus

Kymera Therapeutics Second Quarter 2024 Earnings: Beats Expectations

Simply Wall St.

4 months ago

Kymera Therapeutics Second Quarter 2024 Earnings: Beats Expectations

MT Newswires

4 months ago

Kymera Therapeutics Q2 Net Loss Narrows, Revenue Rises; Shares Fall Pre-Bell

Kymera Therapeutics, Inc. (KYMR) Reports Q2 Loss, Tops Revenue Estimates

Zacks

4 months ago

Kymera Therapeutics, Inc. (KYMR) Reports Q2 Loss, Tops Revenue Estimates

Kymera Therapeutics Announces Second Quarter 2024 Financial Results and Provides a Business Update

GlobeNewswire

4 months ago

Kymera Therapeutics Announces Second Quarter 2024 Financial Results and Provides a Business Update

Kymera Therapeutics to Report Second Quarter 2024 Financial Results on August 7

GlobeNewswire

5 months ago

Kymera Therapeutics to Report Second Quarter 2024 Financial Results on August 7

We're Not Worried About Kymera Therapeutics' (NASDAQ:KYMR) Cash Burn

Simply Wall St.

5 months ago

We're Not Worried About Kymera Therapeutics' (NASDAQ:KYMR) Cash Burn

Biotech Stock Roundup: KYMR, IDYA, QURE Soar on Study Data, HLVX Tanks on Study Failure

Zacks

5 months ago

Biotech Stock Roundup: KYMR, IDYA, QURE Soar on Study Data, HLVX Tanks on Study Failure

Kymera Therapeutics (KYMR) Surges 23.4%: Is This an Indication of Further Gains?

Zacks

5 months ago

Kymera Therapeutics (KYMR) Surges 23.4%: Is This an Indication of Further Gains?

Why Kymera Therapeutics Stock Is Soaring Today

Motley Fool

5 months ago

Why Kymera Therapeutics Stock Is Soaring Today

Investing.com

5 months ago

Kymera Therapeutics soars as Sanofi expands phase 2 trials

Kymera Therapeutics Soars as Sanofi Expands Studies of Its Skin Diseases Drug

Investopedia

5 months ago

Kymera Therapeutics Soars as Sanofi Expands Studies of Its Skin Diseases Drug

Kymera's (KYMR) Partner SNY to Expand Ongoing HS and AD Studies

Zacks

5 months ago

Kymera's (KYMR) Partner SNY to Expand Ongoing HS and AD Studies

MT Newswires

5 months ago

B. Riley Adjusts Price Target on Kymera Therapeutics to $36 From $31, Maintains Neutral Rating

Kymera Therapeutics to Present in Fireside Chat at the UBS Virtual Targeted Protein Degradation Day

GlobeNewswire

5 months ago

Kymera Therapeutics to Present in Fireside Chat at the UBS Virtual Targeted Protein Degradation Day

MT Newswires

5 months ago

Kymera Reports Expansion of KT-474 Trials; Shares Rise After-Hours

Kymera Announces Expansion of KT-474 (SAR444656) HS and AD Phase 2 Studies Following Interim Review of Safety and Efficacy

GlobeNewswire

5 months ago

Kymera Announces Expansion of KT-474 (SAR444656) HS and AD Phase 2 Studies Following Interim Review of Safety and Efficacy

Kymera Therapeutics Presents New Clinical Data from the Ongoing Phase 1 Trial of STAT3 Degrader KT-333 at EHA Annual Meeting

GlobeNewswire

6 months ago

Kymera Therapeutics Presents New Clinical Data from the Ongoing Phase 1 Trial of STAT3 Degrader KT-333 at EHA Annual Meeting

FDA panel votes to recommend Eli Lilly's Alzheimer's drug

Yahoo Finance Video

6 months ago

FDA panel votes to recommend Eli Lilly's Alzheimer's drug

GlobeNewswire

6 months ago

Chu Vision Institute Unveils Comprehensive Guide to LASIK Recovery and Aftercare, Pioneering Patient Care in Minneapolis

California seeks company profits in Big Oil climate lawsuit

Reuters

6 months ago

California seeks company profits in Big Oil climate lawsuit

USA TODAY

6 months ago

S&P 500, Nasdaq post record closing highs; Fed meeting, CPI ahead

Dutch Bros Inc. Announces Launch of Secondary Public Offering of Class A Common Stock

Business Wire

6 months ago

Dutch Bros Inc. Announces Launch of Secondary Public Offering of Class A Common Stock

Ipsen’s Iqirvo® receives U.S. FDA accelerated approval as a first-in-class PPAR treatment for primary biliary cholangitis

GlobeNewswire

6 months ago

Ipsen’s Iqirvo® receives U.S. FDA accelerated approval as a first-in-class PPAR treatment for primary biliary cholangitis

Global Polycaprolactone Market to Record Revenue Worth US$ 1535.5 Mn by 2034; Anticipated to Experience CAGR of 10.3% During 2024 – 2034; states TNR, The Niche Research

GlobeNewswire

6 months ago

Global Polycaprolactone Market to Record Revenue Worth US$ 1535.5 Mn by 2034; Anticipated to Experience CAGR of 10.3% During 2024 – 2034; states TNR, The Niche Research

Media Advisory: Federal Housing Finance Agency Director Sandra Thompson Visits Affordable Apartment Complex in Dallas

Business Wire

6 months ago

Media Advisory: Federal Housing Finance Agency Director Sandra Thompson Visits Affordable Apartment Complex in Dallas

5 Reasons a Biden Second Term Could Be a Financial Disaster for Boomers

GOBankingRates

6 months ago

5 Reasons a Biden Second Term Could Be a Financial Disaster for Boomers

US solar producers could finally have a fighting chance as tariffs kick in on cheaper imports from Asia

Business Insider

6 months ago

US solar producers could finally have a fighting chance as tariffs kick in on cheaper imports from Asia

The Best Woody Perfume For Women

Insider Monkey

6 months ago

The Best Woody Perfume For Women

Microsoft unveils all-digital Xbox consoles, 'Doom' title at Games Showcase

Reuters

6 months ago

Microsoft unveils all-digital Xbox consoles, 'Doom' title at Games Showcase

Insider Monkey

6 months ago

Best Date Night Fragrance in 2024

France's Macron calls snap legislative elections after EU poll blow

AFP

6 months ago

France's Macron calls snap legislative elections after EU poll blow

Dow Jones Futures Due; Apple AI Push, Fed Rate Outlook Lead 8 Big Market Events

Investor's Business Daily

6 months ago

Dow Jones Futures Due; Apple AI Push, Fed Rate Outlook Lead 8 Big Market Events

European Union Vote Delivers Shift to Right, in Blow to French and German Governments

The Wall Street Journal

6 months ago

European Union Vote Delivers Shift to Right, in Blow to French and German Governments

Kymera Therapeutics Presents New Clinical Data from Ongoing Phase 1 Trial of MDM2 Degrader KT-253 at ASCO Annual Meeting

GlobeNewswire

7 months ago

Kymera Therapeutics Presents New Clinical Data from Ongoing Phase 1 Trial of MDM2 Degrader KT-253 at ASCO Annual Meeting

Kymera Therapeutics to Participate in Upcoming June Investor Conferences

GlobeNewswire

7 months ago

Kymera Therapeutics to Participate in Upcoming June Investor Conferences

Kymera Therapeutics to Present New Clinical Data from Ongoing Phase 1 Trial of MDM2 Degrader KT-253 at ASCO Annual Meeting

GlobeNewswire

7 months ago

Kymera Therapeutics to Present New Clinical Data from Ongoing Phase 1 Trial of MDM2 Degrader KT-253 at ASCO Annual Meeting

Kymera Therapeutics Presents New Preclinical Data for KT-621, a First-In-Class, Oral STAT6 Degrader at the ATS Annual Meeting

GlobeNewswire

7 months ago

Kymera Therapeutics Presents New Preclinical Data for KT-621, a First-In-Class, Oral STAT6 Degrader at the ATS Annual Meeting

Kymera Therapeutics to Present New Clinical Data from the Ongoing Phase 1 Trial of STAT3 Degrader KT-333 at EHA Annual Meeting

GlobeNewswire

7 months ago

Kymera Therapeutics to Present New Clinical Data from the Ongoing Phase 1 Trial of STAT3 Degrader KT-333 at EHA Annual Meeting

Kymera Therapeutics to Participate in Upcoming May Investor Conferences

GlobeNewswire

7 months ago

Kymera Therapeutics to Participate in Upcoming May Investor Conferences

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Just Released Its First-Quarter Earnings: Here's What Analysts Think

Simply Wall St.

7 months ago

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Just Released Its First-Quarter Earnings: Here's What Analysts Think

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Q1 2024 Earnings Call Transcript

Insider Monkey

7 months ago

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Q1 2024 Earnings Call Transcript

Kymera (KYMR) Q1 Loss Narrower Than Expected, Pipeline in Focus

Zacks

7 months ago

Kymera (KYMR) Q1 Loss Narrower Than Expected, Pipeline in Focus

Wall Street Analysts Predict a 34.41% Upside in Kymera Therapeutics (KYMR): Here's What You Should Know

Zacks

7 months ago

Wall Street Analysts Predict a 34.41% Upside in Kymera Therapeutics (KYMR): Here's What You Should Know

MT Newswires

8 months ago

Oppenheimer Adjusts Kymera Therapeutics Price Target to $52 From $53

GuruFocus.com

8 months ago

Kymera Therapeutics Inc (KYMR) (Q1 2024) Earnings Call Transcript Highlights: Strategic ...

MT Newswires

8 months ago

Kymera Therapeutics Q1 Net Loss Narrows, Collaboration Revenue Rises

Kymera Therapeutics Announces First Quarter 2024 Financial Results and Provides a Business Update

GlobeNewswire

8 months ago

Kymera Therapeutics Announces First Quarter 2024 Financial Results and Provides a Business Update

Ovid Therapeutics (OVID) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Zacks

8 months ago

Ovid Therapeutics (OVID) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Kymera Therapeutics, Inc. (KYMR) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release

Zacks

8 months ago

Kymera Therapeutics, Inc. (KYMR) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release

20 Counties with the Highest Cancer Rates in the US

Insider Monkey

8 months ago

20 Counties with the Highest Cancer Rates in the US

Kymera Therapeutics to Report First Quarter 2024 Financial Results on May 2

GlobeNewswire

8 months ago

Kymera Therapeutics to Report First Quarter 2024 Financial Results on May 2

Kymera Therapeutics Announces Scientific Presentations at the American Association for Cancer Research 2024 Annual Meeting

GlobeNewswire

8 months ago

Kymera Therapeutics Announces Scientific Presentations at the American Association for Cancer Research 2024 Annual Meeting

Kymera Therapeutics Presents Preclinical Data for STAT6 and TYK2 First-In-Class, Oral Degrader Immunology Programs at the American Academy of Dermatology Annual Meeting

GlobeNewswire

9 months ago

Kymera Therapeutics Presents Preclinical Data for STAT6 and TYK2 First-In-Class, Oral Degrader Immunology Programs at the American Academy of Dermatology Annual Meeting

Insider Sell: CFO Bruce Jacobs Sells 3,934 Shares of Kymera Therapeutics Inc (KYMR)

GuruFocus.com

9 months ago

Insider Sell: CFO Bruce Jacobs Sells 3,934 Shares of Kymera Therapeutics Inc (KYMR)

Analysts' Revenue Estimates For Kymera Therapeutics, Inc. (NASDAQ:KYMR) Are Surging Higher

Simply Wall St.

10 months ago

Analysts' Revenue Estimates For Kymera Therapeutics, Inc. (NASDAQ:KYMR) Are Surging Higher

Kymera Therapeutics to Participate in Upcoming March Investor Conferences

GlobeNewswire

10 months ago

Kymera Therapeutics to Participate in Upcoming March Investor Conferences

Earnings Update: Kymera Therapeutics, Inc. (NASDAQ:KYMR) Just Reported And Analysts Are Trimming Their Forecasts

Simply Wall St.

10 months ago

Earnings Update: Kymera Therapeutics, Inc. (NASDAQ:KYMR) Just Reported And Analysts Are Trimming Their Forecasts

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Q4 2023 Earnings Call Transcript

Insider Monkey

10 months ago

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Q4 2023 Earnings Call Transcript

Share on Social Networks: